Study S001594

A 6-month, Multi-centre, Open Labelled, Non-randomized, Non-interventional, Safety Study of Liraglutide (Victoza®) in Subjects With Type 2 Diabetes Mellitus in Korea

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01821846
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 64
Start: 2013-11-20
Primary completion: 2017-03-08
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide
Results posted: FALSE
Secondary identifiers: OTHER:U1111-1132-2221

Registered primary outcomes

The incidence of SADRs (Serious Adverse Drug Reactions) [Up to 6 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.